UK-based CellCentric Ltd has secured a new investment from an arm of the American Cancer Society to progress a small molecule drug for multiple cancer indications. The investment, from BrightEdge, the cancer society’s philanthropic venture capital fund, will support clinical development of inobrodib, a candidate treatment for prostate and other cancers. Simultaneously, Morningside Investments Ltd, an existing investor, is increasing its financial support for the company. Both financing deals are equity investments, the size of which was not disclosed.
